Crescent Biopharma (CBIO) Amortizatization of Intangibles (2020 - 2026)
Crescent Biopharma (CBIO) has disclosed Amortizatization of Intangibles for 8 consecutive years, with $97000.0 as the latest value for Q1 2026.
- For Q1 2026, Amortizatization of Intangibles changed N/A year-over-year to $97000.0; the TTM value through Mar 2026 reached $215000.0, down 39.78%, while the annual FY2025 figure was $212000.0, 47.35% down from the prior year.
- Amortizatization of Intangibles hit $97000.0 in Q1 2026 for Crescent Biopharma, up from $95000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $227190.0 in Q3 2023 and bottomed at $23000.0 in Q2 2025.
- Average Amortizatization of Intangibles over 5 years is $172151.7, with a median of $201239.5 recorded in 2022.
- Year-over-year, Amortizatization of Intangibles rose 10.21% in 2023 and then fell 22.61% in 2024.
- Crescent Biopharma's Amortizatization of Intangibles stood at $213848.0 in 2022, then fell by 12.33% to $187482.0 in 2023, then dropped by 9.55% to $169571.0 in 2024, then crashed by 43.98% to $95000.0 in 2025, then grew by 2.11% to $97000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods came in at $97000.0, $95000.0, and $23000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.